The potential protective effect of Renin-angiotensin system (RAS) inhibitors is a subject of increasing interest due to their possible role as chemopreventive agents against colorectal cancer (CRC). To evaluate this association, we conducted a case-control study with 2,165 cases of colorectal cancer, diagnosed between 2007 and 2012, and 3,912 population controls frequency matched (by age, sex and region) from the Spanish multicenter case-control study MCC-Spain. We found a significant protective effect of the Angiotensin-converting enzyme Inhibitors (ACEIs) against CRC, limited to the under-65 years group (OR=0.65 95%CI (0.48-0.89)) and to a lesser degree to men (OR=0.81 95%CI (0.66-0.99). In contrast, the angiotensin receptor blockers (ARBs) did not show a significant effect. Regarding the duration of use, a greater protection was observed in men as the length of consumption increases. In contrast, in the under-65 stratum, the strongest association was found in short-term treatments. Finally, by analyzing ACEIs effect by colon subsite, we found no differences, except for under 65 years old, where the maximum protection was seen in the proximal intestine, descending in the distal and rectum (without statistical significance). In conclusion, our study shows a protective effect on CRC of the ACEis limited to males and people under 65 years old, which increases in proximal colon in the latter. If confirmed, these results may suggest a novel approach to proximal CRC prevention, given the shortcomings of colonoscopy screening in this location.
INTRODUCTION
Colorectal cancer (CRC) is one of the most common forms of cancer worldwide with approximately 450,000 new cases detected in Europe in 2012 [1, 2] . In the last decades, the field of chemoprevention has experimented a rising interest, with the use of certain drugs to reduce the individual risk of cancer. Nowadays, the role of aspirin therapy in the reduction of colorectal cancer risk and precancerous adenomas [3, 4] is well known and there is increasing evidence of the chemopreventive effect of many others drugs used for cardiovascular diseases such as statins [5] and renin-angiotensin system (RAS) inhibitors [6] . In addition, recent observational studies and one meta-analysis have shown a protective effect of RAS therapy against CRC [7] [8] [9] [10] . Despite these encouraging findings, other studies have yielded conflicting results [11] [12] [13] , calling for additional studies before recommending the clinical use of RAS inhibitors for CRC chemoprevention. The mechanism of action of the RAS-inhibitors combines both pro and antitumor effects, probably explain the controversial results obtained in observational studies. Moreover, the potential interaction with lifestyle factors (eg, diet) warrants more investigation [14] . Finally, it is important to identify whether there is a differential effect regarding the tumor anatomic subsite, given that, to the best of our knowledge, no previous studies have analyzed these aspects.
Therefore, the purpose of this work is to evaluate the effects of Angiotensinconverting-enzyme inhibitors (ACEis) and Angiotensin receptor blockers (ARBs) on overall colorectal cancer risk, and on its different anatomic locations, in a large population-based case-control study conducted in Spain, the MCC-Spain study.
MATERIALS AND METHODS

Study design and population
We conducted a multi-region case-control study "the Spanish multicase-control study" (MCC-Spain). This study was designed with the main objective of investigating lifetime environmental, infectious, medical and occupational exposures, as well as genetic factors associated with five cancer sites. Briefly, the MCC-Spain is a population-based case-control study of common tumors in Spain; the recruitment includes histologically confirmed incident cases of colorectal cancer diagnosed between January 1st, 2007 and March 31st, 2012. The cases were enrolled in 23 hospitals and primary care centers in 12 Spanish provinces together with a common set of matched population controls. Controls with no prior history of CRC
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cancer were randomly selected from lists of primary care centers, according to age, sex and regional distribution of the cases included in the study. Response rates were 68% for colon cancer cases and 53% for controls, with no differences in the main socio-demographic variables among those who participated and those who refused to participate. The Ethics
Committees of participating hospitals approved the study protocols, and participants provided written informed consent at the time of their inclusion in the study. Detailed clinical information was collected for all cases. The questionnaire is available on the website of the study (www.mccspain.org). Further information can be found elsewhere [15] . In the present study, we have selected only the 2,165 colorectal cancer cases recruited in MCC-Spain and their 3,912 frequency matched controls.
Data collection
Participants were interviewed face-to-face by trained monitors with a comprehensive epidemiological questionnaire that assessed socio-demographic information, personal and family history of cancer, anthropometric data, lifestyle, environmental exposure and medical history of medication/drugs use. To allow for a minimum latency period, all potential confounders that could be modified by the disease (tobacco and alcohol consumption, diet)
were censored to 1 year prior to the interview. Regarding the life style, diet (including alcohol intake) was assessed with the use of a validated semi-quantitative Spanish Food Frequency Questionnaire (FFQ), which was modified to include regional products. The FFQ included 140 food items, and assessed usual dietary intake during the previous year.
Drug use assessment
Drugs use was recorded by indication. For each drug, the brand name, dose and duration of exposure were recorded to identify patients with regular drug consumption ("no and occasionally" versus "yes") and the duration of consumption (more or less than 5 years).
The drugs were coded by following the Anatomical Therapeutic Chemical Classification System (ATC codes) to define groups with similar mechanisms of action [16] . The ATC code included in the present analysis is code C09 (Agents acting on the renin-angiotensin system). We performed the analyses for ACEis drugs and for ARBs. For each of these analyses, we had as reference never having used the drug in question. We analyzed separately each colon subsite:
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A C C E P T E D M A N U S C R I P T proximal colon (including cecum, ascending colon, transverse and hepatic and splenic flexures), distal colon (including descending colon, sigmoid and recto-sigmoid junction) and rectum. Anatomic subsites were defined according to Li et al [17] .
Statistical Methods
Unconditional logistic regression was used to assess the association between treatment of 
RESULTS
During the study period, data from 2,165 colorectal cancer cases and 3,912 population controls were collected. The characteristics of cases and controls are shown in Table 1 . The main differences between cases and controls were found at educational level, family history of colon cancer and diet. Controls had higher educational level and less often had a first-degree relative with colorectal cancer. Finally, regarding eating habits, controls had lower ethanol, energy and red meat intake and higher intake of vegetable.
RAS inhibitors and colorectal cancer
A C C E P T E D M A N U S C R I P T Table 2 ).
Finally, considering the influence of length of consumption (Table 3) , an opposite (regarding the length of consumption) effect was observed in men and in the under-65 group.
While in the men group, long-term treatments presented the greatest protection (OR=0.71 the overall analysis, nor in the stratified analysis by sex, age and BMI factors (Table 5) .
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DISCUSSION
In this study, we analyzed a population-based case control study for evaluating the potential effect of RAS inhibitors on CRC. Our study shows a relevant protective effect against CRC for the ACEis limited to the under-65 group and to men, but no effect for the ARBs. The stronger association was observed in the under 65-year men where the ACEis show a protective effect in short term treatments. However, in men over 65, only the length of consumption greater than five years showed a protective effect.
Up to now, existing data regarding the effect of ACEis/ARBs on overall cancer risk are contradictory [18] [19] [20] [21] . Randomized trials exploring this association usually have follow-up of less than five years, insufficient to detect cancer development. Moreover, they focus on cardiovascular outcomes as predefined clinical endpoints, being the cancer risk a 'post-hoc'
analysis, thus possibly underreported. For these reasons, we limit our discussion to observational studies specifically designed to evaluate cancer. Most of the studies published in the last 5 years focusing on CRC have shown that the use of ACEis alone or combined with
ARBs is associated with a decrease in the risk of CRC development [6, 7, 9] , as well as in advanced adenomatous colon polyps [8] or advanced neoplasia. In addition, a recently published meta-analysis of observational studies [10] also found a protective effect of the combination of ACEis or ARBs against CRC. Regarding overall ACEis effect, we found a similar protection to that found in other studies combining ACEis and ARBs in their analyses [9, 10] , but our results found only borderline significance. It is remarkable that this protection increased substantially in the under 65-year age group and less markedly in men. The influence of sex on colon cancer incidence is widely known and these differences increase progressively across the colon from the cecum to the rectum. Men have higher rates of CRC than women, probably due to sex-specific exposure to risk factors, differences in screening experiences and access to medical care and protective effects of both endogenous and exogenous hormones [22, 23] . In addition, the differential expression of estrogen receptors between the colonic subsites might explain the right-sided predominance of the neoplasm in women, even though the etiological role of these receptors is not yet well understood [24, 25] . Some studies suggest that, over time, the effectiveness of ACE inhibition is diminished in women [26] . These differences could be due to a modulatory effect of the sexual steroids on the expression and activity of the various components of the RAS, which would explain why the protective effect of ACEis was observed only in males in our study [27] . Regarding age differences, a gradual increase in the ratios of proximal-to-distal CRC with advancing age has been observed [28] [29] [30] .
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Finally, two recent meta-analyses have shown the influence of obesity and excess weight on the risk of developing CRC [31, 32] . Although most of the studies that have conducted analyses by CRC subsite have found a significant association between body size and distal adenomas or cancer, to date, evidence is still inconsistent [33] .
Regarding the exposure time, we observed that the protective effect increased in longterm treatment (>5 years) only in men, while in the under-65 subgroup the protective effect was seen only in treatments lasting less than five years. However, the number of cases and controls under-65 exposed to ACEIs for more than five years was rather scarce, which makes it difficult to identify a length of treatment -effect relationship. Makar et al [9] , also in a casecontrol study, found a clear association between long-term or high dose of RAS inhibitors and CRC protection.
On the other hand, the lack of association between ARBs therapy and CRC is consistent with others studies [11, 34, 35] , which also studied separately the effect of ARBs. In contrast, Azoulay et al [7] , in a case-control study nested in a cohort, found a weak, but significant protection (OR=0.90 95% CI (0.83-0.98)). Focusing on colorectal carcinogenesis, one experimental study [36] has demonstrated a beneficial effect of ACEi or ARB therapy reducing the total number of colonic premalignant lesions in obese mice. The role of angiotensin II in cell proliferation, cell migration, and angiogenesis suggests their participation in certain steps of tumor genesis and progression [37] , and could explain the antitumor effect of the RAS inhibitors (inhibiting tumor angiogenesis, inducing cancer cell apoptosis and disrupting the microenvironment of tumor) [38, 39] . However, the mechanisms of action of the two types of RAS drugs, ACEis and ARBs, are quite different. While ACEis act inhibiting the conversion of angiotensin I to angiotensin II, ARBs act on the receptors of this hormone. The protective effect of ACEis has been demonstrated in animal models of solid cancers [40, 41] , but certain authors have also found that the chronic treatment with ACEis might produce the accumulation of some peptides with protumor effect, such as bradykinin, substance P, and Nacetyl-seryl-aspartyl-lysyl-proline [42] . ARBs, in turn, selectively block the angiotensin II type 1 receptors, responsible for vasoconstriction, cell growth, and sympathetic activation and in this way exerts their potential antineoplastic effect, maintaining the beneficial effects of angiotensin II type 2-receptor stimulation (vasodilatory and antiproliferative action mediated via the kinin system) [21, 37] . Nevertheless, some studies have suggested a pro-tumoral effect of the ARBs as a result of the stimulation of free angiotensin II type 2-receptor, which results in increased tumor progression [18, 43, 44] .
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In the last decades, diverse reports have suggested that CRC is a heterogeneous disease [45] . At first, distinguishing two distinct categories of CRC, proximal and distal, was proposed. Thereafter rectal cancer, which is usually discussed together with colon cancer, was addressed specifically as another type of CRC [16] . This is the reason why we have analyzed separately the effect of RAS inhibitors according to the colon subsite. Our results show that the protective effect observed for ACEis did not reach statistical significance in the analysis by location. In the same way, ARBs did not show effect in any of the three locations. However, in the under-65 group, ACEis showed a lower protective effect as one progresses through the large intestine. Thus, maximum protection was seen in the proximal intestine, descending in the distal intestine and rectum, in this last case without statistical significance. In the same way, Kedika et al reported a statistically significant decrease in right sided polyps in ACE-I users. The fact that young people are less susceptible to developing right-sided colon cancer
[23] suggests a synergistic interaction between ACEis and age.
To the best of our knowledge, this is the first study separately addressing the influence of the RAS inhibitors on CRC by colon location. It has been speculated that the risk factors for CRC may vary according to their anatomic location, because these structures arise from different embryonic tissue (the proximal colon from midgut and distal and rectum from hindgut) and serve different functions [45, 46] .
Strengths and limitations
The strengths of this case-control study include, first, the enrollment of newly diagnosed colorectal cancer cases, verified with revision of the medical record and the pathological anatomy report, and population controls. Furthermore, all the information has been collected by personal interviews identically for cases and controls. This strategy allows us to control the principal confounding factors in the relation of RAS inhibitors and colorectal cancer (such as family history of colorectal cancer, smoke status, alcohol consumption, age or BMI) and include these variables in the adjusted analyses. Notwithstanding these strengths, our study has several limitations. First, we used self-reported drug use whereas most studies use pharmacy records or prescribing information. Although the validity of self-reported medication use has not been assessed in our study, other studies comparing self-reported use of antihypertensive medications with pharmacy databases [47] or physician reports [48] have showed that self-report is reasonably valid (sensitivity and specificity both being about 90%).
Second, we were unable to explore a possible association between specific types of drugs previously associated with cancer (e.g. Lisinopril, Captopril, Losartan, Candesartan or Telmisartan), due to the small number of exposed in our study. Third, unfortunately, we could ACCEPTED MANUSCRIPT
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not explore a dose-response effect of the drugs studied due to the poor quality of these data.
Therefore, to approach the intensity of the relationship we have chosen to use the duration of treatment, considering more exposed those that took the treatment for more than 5 years.
CONCLUSIONS
Our study found a protective effect on the CRC risk of the ACEis limited to the under-65 group and less markedly in men. In those aged under 65 years, this protection shows a descending gradient across the colon and disappears in the rectum. Age and sex were modifiers of this association. We found no evidence of any effect on colorectal cancer risk among those exposed to the ARBs.
The potential protective effect of RAS inhibitors is a subject of increasing interest due to their possible role as chemopreventive agents against CRC [6, 14] , but to date, there are still few studies that address this relationship. Further work is required to confirm these results, but our findings could represent a promising progress in CRC prevention, given the poorer results obtained with colonoscopy screening in proximal colon. 
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A C C E P T E D M A N U S C R I P T Red meat intake (g/day), Fruit intake (g/day), Vegetable intake (g/day), CI: confidence interval Red meat intake (g/day), Fruit intake (g/day), Vegetable intake (g/day), CI: confidence interval Odds ratio adjusted for age, recruitment area, education level, tobacco smoking history, BMI, family history of colorectal cancer, Ethanol intake (g/day) Red meat intake (g/day), Fruit intake (g/day), Vegetable intake (g/day), CI: confidence interval 
A C C E P T E D M A N U S C R I P T Table 5 . Relationship between Angiotensin receptor blockers and colon cancer by location OR: Odds ratio adjusted for age, recruitment area, education level, tobacco smoking history, BMI, family history of colorectal cancer,. Ethanol intake (g/day) Red meat intake (g/day), Fruit intake (g/day), Vegetable intake (g/day), CI: confidence interval 1 All cases were diagnosed between 2007 and 2012.
Population
Cancer type Unexposed controls / cases (n) Exposed controls/cases (n) OR (95% CI)
